Systematic Analysis of the Associations between Adverse Drug Reactions and Pathways

Adverse drug reactions (ADRs) are responsible for drug candidate failure during clinical trials. It is crucial to investigate biological pathways contributing to ADRs. Here, we applied a large-scale analysis to identify overrepresented ADR-pathway combinations through merging clinical phenotypic data, biological pathway data, and drug-target relations. Evaluation was performed by scientific literature review and defining a pathway-based ADR-ADR similarity measure. The results showed that our method is efficient for finding the associations between ADRs and pathways. To more systematically understand the mechanisms of ADRs, we constructed an ADR-pathway network and an ADR-ADR network. Through network analysis on biology and pharmacology, it was found that frequent ADRs were associated with more pathways than infrequent and rare ADRs. Moreover, environmental information processing pathways contributed most to the observed ADRs. Integrating the system organ class of ADRs, we found that most classes tended to interact with other classes instead of themselves. ADR classes were distributed promiscuously in all the ADR cliques. These results reflected that drug perturbation to a certain pathway can cause changes in multiple organs, rather than in one specific organ. Our work not only provides a global view of the associations between ADRs and pathways, but also is helpful to understand the mechanisms of ADRs.

[1]  P. Lampe,et al.  Characterization of the Mitogen-activated Protein Kinase Phosphorylation Sites on the Connexin-43 Gap Junction Protein (*) , 1996, The Journal of Biological Chemistry.

[2]  A. Marks.  Intracellular calcium-release channels: regulators of cell life and death. , 1997, The American journal of physiology.

[3]  A. Clerk,et al.  "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. , 1998, Circulation research.

[4]  M. Hori,et al.  Functional role of c-Src in gap junctions of the cardiomyopathic heart. , 1999, Circulation research.

[5]  B. Roth,et al.  The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .

[6]  G. Heusch,et al.  Mitogen-activated protein kinases in the heart , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  Marc Evans,et al.  Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle , 2002, Drug safety.

[8]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[9]  E. Brown,et al.  Methods and Pitfalls in Searching Drug Safety Databases Utilising the Medical Dictionary for Regulatory Activities (MedDRA)1 , 2003, Drug safety.

[10]  D. Furst,et al.  Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. , 2004, Rheumatology.

[11]  Daniel C. Liebler,et al.  Elucidating mechanisms of drug-induced toxicity , 2005, Nature Reviews Drug Discovery.

[12]  Illés J. Farkas,et al.  CFinder: locating cliques and overlapping modules in biological networks , 2006, Bioinform..

[13]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[14]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[15]  S. Ha,et al.  [Clinical features of acute viral hepatitis A complicated with acute renal failure]. , 2007, The Korean journal of hepatology.

[16]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[17]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[18]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[19]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[20]  Bin Chen,et al.  Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..

[21]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[22]  Chunquan Li,et al.  SubpathwayMiner: a software package for flexible identification of pathways , 2009, Nucleic acids research.

[23]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..

[24]  M. Milik,et al.  Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.

[25]  Shi-Hua Zhang,et al.  Disease-Aging Network Reveals Significant Roles of Aging Genes in Connecting Genetic Diseases , 2009, PLoS Comput. Biol..

[26]  Roded Sharan,et al.  An Algorithmic Framework for Predicting Side-Effects of Drugs , 2010, RECOMB.

[27]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[28]  Navdeep Jaitly,et al.  A Structure-Based Approach for Mapping Adverse Drug Reactions to the Perturbation of Underlying Biological Pathways , 2010, PloS one.

[29]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[30]  H. Vaudry,et al.  Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. , 2011, Current pharmaceutical design.

[31]  H. Ohta,et al.  Pathophysiological roles of FGF signaling in the heart , 2013, Front. Physiol..

[32]  M. Peeters,et al.  Antineoplastic therapy-induced pulmonary toxicity , 2013, Expert review of anticancer therapy.

[33]  Goran Nenadic,et al.  PathNER: a tool for systematic identification of biological pathway mentions in the literature , 2013, BMC Systems Biology.

[34]  C. Cipolla,et al.  Managing Cardiotoxicity of Chemotherapy , 2013, Current Treatment Options in Cardiovascular Medicine.

[35]  Xiaobo Zhou,et al.  Integrating Genomics and Proteomics Data to Predict Drug Effects Using Binary Linear Programming , 2014, PloS one.